La Jolla Institute for Allergy & Immunology, La Jolla, CA, United States of America.
Department of Medicine, Division of Pulmonary and Critical Care Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, United States of America.
PLoS One. 2018 Oct 10;13(10):e0204620. doi: 10.1371/journal.pone.0204620. eCollection 2018.
Whole extract or allergen-specific IgE testing has become increasingly popular in the diagnosis of peanut allergy. However, much less is known about T cell responses in peanut allergy and how it relates to different clinical phenotypes. CD4+ T cells play a major role in the pathophysiology of peanut allergy as well as tolerance induction during oral desensitization regimens. We set out to characterize and phenotype the T cell responses and their targets in peanut sensitized patients. Using PBMC from peanut-allergic and non-allergic patients, we mapped T cell epitopes for three major peanut allergens, Ara h 1, 2 and 3 (27 from Ara h 1, 4 from Ara h 2 and 43 from Ara h 3) associated with release of IFNγ (representative Th1 cytokine) and IL5 (representative Th2 cytokine). A pool containing 19 immunodominant peptides, selected to account for 60% of the total Ara h 1-3-specific T cell response in allergics, but only 20% in non-allergics, was shown to discriminate T cell responses in peanut-sensitized, symptomatic vs non-symptomatic individuals more effectively than peanut extract. This pool elicited positive T cell responses above a defined threshold in 12/15 sensitized, symptomatic patients, whereas in the sensitized but non-symptomatic cohort only, 4/14 reacted. The reactivity against this peptide pool in symptomatic patients was dominated by IL-10, IL-17 and to a lesser extend IL-5. For four distinct epitopes, HLA class II restrictions were determined, enabling production of tetrameric reagents. Tetramer staining in four donors (2 symptomatic, 2 non-symptomatic) revealed a trend for increased numbers of peanut epitope-specific T cells in symptomatic patients compared to non-symptomatic patients, which was associated with elevated CRTh2 expression whereas cells from non-symptomatic patients exhibited higher levels of Integrin β7 expression. Our results demonstrate differences in T cell response magnitude, epitope specificity and phenotype between symptomatic and non-symptomatic peanut-sensitized patients. In addition to IgE reactivity, analysis of peanut-specific T cells may be useful to improve our understanding of different clinical manifestations in peanut allergy.
整体提取物或过敏原特异性 IgE 检测在花生过敏的诊断中越来越受欢迎。然而,对于花生过敏中的 T 细胞反应及其与不同临床表型的关系,我们了解得要少得多。CD4+T 细胞在花生过敏的病理生理学以及口服脱敏方案中的诱导耐受中起着重要作用。我们着手描述和表型化花生致敏患者的 T 细胞反应及其靶标。使用来自花生过敏和非过敏患者的 PBMC,我们绘制了三种主要花生过敏原 Ara h 1、2 和 3 的 T 细胞表位(来自 Ara h 1 的 27 个,来自 Ara h 2 的 4 个和来自 Ara h 3 的 43 个),与 IFNγ(代表性 Th1 细胞因子)和 IL5(代表性 Th2 细胞因子)的释放相关。一个包含 19 个免疫显性肽的池,这些肽被选择以占过敏者中总 Ara h 1-3 特异性 T 细胞反应的 60%,而非过敏者中仅占 20%,被证明比花生提取物更有效地区分花生致敏、有症状与无症状个体的 T 细胞反应。该池在 15 名致敏、有症状的患者中 12 名中引起了高于定义阈值的阳性 T 细胞反应,而在致敏但无症状的队列中仅 4 名反应。在有症状的患者中,针对该肽池的反应主要由 IL-10、IL-17 和在较小程度上由 IL-5 引起。对于四个不同的表位,确定了 HLA Ⅱ类限制,从而能够产生四聚体试剂。在四个供体(2 名有症状,2 名无症状)中进行四聚体染色显示,与无症状患者相比,有症状患者中花生表位特异性 T 细胞的数量增加,这与升高的 CRTh2 表达相关,而无症状患者的细胞表现出更高水平的整合素β7 表达。我们的结果表明,有症状和无症状花生致敏患者之间的 T 细胞反应幅度、表位特异性和表型存在差异。除了 IgE 反应性外,分析花生特异性 T 细胞可能有助于我们更好地理解花生过敏的不同临床表现。